# KEYNOTE-240 (NCT02702401)

> Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: previously systemically treated advanced hepatocellular carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02702401
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Hepatocellular Carcinoma
- Interventions: Pembrolizumab; Placebo; Best Supportive Care
- Enrollment: 413
- Primary outcome: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on KEYNOTE-240 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 24 posts on X
- 4 podcast episodes
- 2 YouTube videos

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=keynote-240-nct02702401

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02702401", "email": "<work email>"}; the inbox owner confirms by the emailed link.